Matthijs Smith

Canaccord Genuity

Image: Matthijs Smith

Matthijs Smith joined Canaccord Genuity in September 2012 as a senior analyst specializing in Australian life science companies. Smith has more than eight years' experience as equities analyst at Shaw Stockbroking, Lodge Partners Pty Ltd. and Patersons Securities, where he focused on emerging companies developing new pharmaceutical and medical device-based therapies. Prior to moving into the capital markets, he held senior executive roles in the biotech industry, as well as worked at the Boston Consulting Group. Smith has several years' experience in medical research, including earning a Ph.D. from University of London and conducting postdoctoral research at the University of Melbourne. He also worked as an assistant editor at the journal Nature. He holds an master's degree in business administration from Melbourne Business School in Australia.

Recent Quotes

"IPD is now well cashed up to drive sales of the L-Dex lymphoedema test."

— Matthijs Smith, Canaccord Genuity (1/27/15)
more >

"CMS has assigned a $112.67 reimbursement rate for IPD's L-Dex test."

— Matthijs Smith, Canaccord Genuity (11/3/14)
more >

"IPD's appointment of Dr. Frank Vicini should raise L-Dex's profile."

— Matthijs Smith, Canaccord Genuity (9/8/14)
more >

"IPD's major milestone has secured the expanded market; we are increasing our target price."

— Matthijs Smith, Canaccord Genuity (9/3/14)
more >

"IPD's device allows the physician to detect lymphedema 200 days earlier than with a tape measure."

The Life Sciences Report Interview with Matthijs Smith (8/28/14)
more >

Due to permission requirements, not all quotes are shown.